INBRX-105 - PDL1x41BB antibody + Pembrolizumab
Phase 1Terminated 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Solid Tumors
Conditions
Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
Trial Timeline
Jan 30, 2019 → Oct 3, 2024
NCT ID
NCT03809624About INBRX-105 - PDL1x41BB antibody + Pembrolizumab
INBRX-105 - PDL1x41BB antibody + Pembrolizumab is a phase 1 stage product being developed by Inhibrx Biosciences for Metastatic Solid Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT03809624. Target conditions include Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03809624 | Phase 1 | Terminated |
Competing Products
20 competing products in Metastatic Solid Tumors